Telix Pharmaceuticals Faces Investor Lawsuit Following Regulatory Setbacks
Table of Contents
A securities class action lawsuit has been filed against Telix Pharmaceuticals Limited (NASDAQ: TLX), capping a period of critically important turmoil for the biopharmaceutical company. The legal action follows revelations of an SEC investigation and a rejection letter from the Food and Drug Administration (FDA), both of which contributed to a sharp decline in the company’s stock price.
Investor Claims and Investigation Details
National shareholder rights firm Hagens Berman is leading the investigation into potential legal claims and is urging investors who experienced significant losses to submit their losses. The firm is also seeking individuals with relevant knowledge to come forward and assist in the investigation.
The proposed class period for the lawsuit is February 21,2025,through August 28,2025,with a lead plaintiff deadline of January 9,2026. the case, thomas v. Telix Pharmaceuticals Ltd., et al.,No. 1:25-cv-02299 (D. ind.), centers on allegations that Telix made false and misleading statements regarding it’s prostate cancer therapeutic candidates (TLX591 and TLX592) and its zircaix diagnostic candidate for kidney cancer.
Allegations of Misleading Statements
During the class period, Telix reportedly assured investors of “great progress” across its therapeutic pipeline, specifically highlighting late-stage assets in brain, kidney, and prostate cancer programs, which were in Phase 3 trials.the company also emphasized its “truly global manufacturing capability” as a key competitive advantage.
Tho,the lawsuit alleges that Telix overstated the progress of its prostate cancer therapies and misrepresented the quality of its supply chain and manufacturing partnerships.
SEC Investigation and FDA Rejection
The catalyst for the recent downturn began on July 22, 2025, when Telix disclosed it was under investigation by the Securities and Exchange Commission (SEC) regarding disclosures related to the development of its prostate cancer candidates, TLX591 and TLX592. This news prompted a significant drop in the price of Telix’s American Depositary Shares (ADSs).
Further compounding the issues,on August 28,2025,Telix announced it had received a Complete Response Letter (CRL) from the FDA for its Zircaix Biologics License Application (BLA). The CRL cited deficiencies in chemistry, manufacturing, and controls, and requested additional data to demonstrate consistency between the drug product used in clinical trials and the intended commercial manufacturing process. The FDA also identified deficiencies with Telix’s third-party manufacturing and supply chain partners, requiring remediation before the BLA can be resubmitted. This declaration led to another substantial decline in telix’s ADS price.
Firm’s outlook and Call for Information
“We’re investigating claims that Telix may have misled investors about the development and commercial prospects of TLX591, TLX591 and Zircaix, and weather other of the company’s therapies might potentially be at issue,” stated Reed Kathrein, a partner at Hagens Berman leading the investigation.
Investors who have experienced losses and individuals with non-public information regarding Telix are encouraged to contact Hagens Berman. The firm also highlights the potential for whistleblowers to receive rewards of up to 30% of any accomplished recovery obtained by the SEC through its whistleblower programme.
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights firm specializing in complex litigation,with a focus on corporate accountability. The firm has secured over $2.9 billion in settlements and judgments on behalf of investors,whistleblowers,workers,and consumers.
Contact: Reed Kathrein, 844-916-0895.
reader question:– what is the lawsuit about? The lawsuit alleges Telix made false and misleading statements about its prostate cancer therapies and Zircaix. The SEC is investigating disclosures related to the development of TLX591, TLX592.
